

RECEIVED

SEP 30 2003



TECH CENTER 16.0/2000

# PATENT

Customer No. 020462

**Attorney Docket No. P31251C1**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re Application of:**

**Andrew CRAIG et al.**

**Serial No.: 09/469,902**

**Filed: December 22, 1999**

For: METHOD OF USING PAROXETINE  
DERIVATIVES

**Group Art Unit: 1625**

Examiner: CHANG, C.

Commissioner for Patents and Trademarks  
Washington, DC 20231

Sir,

RECEIVED  
SEP 29 2003  
TC 1700

**TERMINAL DISCLAIMER**

Assignee, SmithKline Beecham plc, duly organized under the laws of the United Kingdom and having its principal place of business at Great West Road, Brentford, Middlesex TW8 9EP, through its attorneys, represents that it is the assignee of the entire right, title, and interest in and to the instant application, Application No. 09/469,902, filed December 22, 1999, in the names of Andrew CRAIG, Victor JACEWICZ, and Michael URQUHART by assignment duly recorded for the parent application, 09/299,060, in the United States Patent and Trademark Office at Reel 9917, Frame 0147 on April 23, 1999, and at Reel 010590, Frame 0254 on February 4, 2000.

Assignee hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154 to 156

and 173, as presently shortened by any terminal disclaimer, of U.S. Patent No. 6,063,927. Assignee hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, Assignee does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that the prior patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or in part, is terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

In accordance with the fee schedule set forth in 37 C.F.R. § 1.20(d), the required fee of \$110.00 is being filed with this disclaimer. If a check for the required fee is not filed concurrently herewith or if there are any additional fees due in connection with the filing of this Terminal Disclaimer, please charge the fees to our Deposit Account No. 19-2570.

The undersigned is an attorney of record.

Respectfully submitted,

Dated: 9/24/03

By: Charles M. Kinzig  
Charles M. Kinzig  
Vice President, Corporate Intellectual  
Property for GlaxoSmithKline  
Reg. No. 33,252